The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

autoimmunity

23rd Apr 2025

Plain language summary of a review on omalizumab for treating chronic spontaneous urticaria

This plain language summary explains, in simple terms, the results of a study from 2022 discussing a biosimilar medicine called GP2017 (called SDZ-ADL in this summary, sold as Hyrimoz®). This medicine is used to treat people with inflammatory conditions. This study investigated a new, high-concentration formulation of GP2017 (SDZ-ADL-HCF) in order to show that the high concentration option acts the same way in the body as SDZ-ADL

22nd Jan 2024

autoimmunity

Plain language summary of a review on omalizumab for treating chronic spontaneous urticaria

Two different concentrations of GP2017 (a biosimilar medicine) are associated with similar drug levels in the body- a plain language summary